JP2022546557A5 - - Google Patents

Info

Publication number
JP2022546557A5
JP2022546557A5 JP2022514209A JP2022514209A JP2022546557A5 JP 2022546557 A5 JP2022546557 A5 JP 2022546557A5 JP 2022514209 A JP2022514209 A JP 2022514209A JP 2022514209 A JP2022514209 A JP 2022514209A JP 2022546557 A5 JP2022546557 A5 JP 2022546557A5
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
phosphate
group
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022514209A
Other languages
English (en)
Japanese (ja)
Other versions
JP7672394B2 (ja
JP2022546557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049261 external-priority patent/WO2021046260A1/en
Publication of JP2022546557A publication Critical patent/JP2022546557A/ja
Publication of JP2022546557A5 publication Critical patent/JP2022546557A5/ja
Application granted granted Critical
Publication of JP7672394B2 publication Critical patent/JP7672394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514209A 2019-09-03 2020-09-03 治療的に活性な複合体のアシアロ糖タンパク質受容体媒介送達 Active JP7672394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962895417P 2019-09-03 2019-09-03
US62/895,417 2019-09-03
PCT/US2020/049261 WO2021046260A1 (en) 2019-09-03 2020-09-03 Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates

Publications (3)

Publication Number Publication Date
JP2022546557A JP2022546557A (ja) 2022-11-04
JP2022546557A5 true JP2022546557A5 (cg-RX-API-DMAC7.html) 2023-09-13
JP7672394B2 JP7672394B2 (ja) 2025-05-07

Family

ID=74680487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514209A Active JP7672394B2 (ja) 2019-09-03 2020-09-03 治療的に活性な複合体のアシアロ糖タンパク質受容体媒介送達

Country Status (9)

Country Link
US (1) US12290567B2 (cg-RX-API-DMAC7.html)
EP (1) EP4025252A4 (cg-RX-API-DMAC7.html)
JP (1) JP7672394B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220058578A (cg-RX-API-DMAC7.html)
CN (1) CN114929282B (cg-RX-API-DMAC7.html)
AU (1) AU2020340987B2 (cg-RX-API-DMAC7.html)
CA (1) CA3152529A1 (cg-RX-API-DMAC7.html)
IL (1) IL290766B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021046260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230227826A1 (en) * 2020-06-18 2023-07-20 Arcturus Therapeutics, Inc. Una oligomers for the treatment of polyglutamine diseases
WO2021257916A1 (en) * 2020-06-18 2021-12-23 Arcturus Therapeutics, Inc. Una oligomers for the treatment of polyglutamine diseases
EP4763287A2 (en) 2021-09-03 2026-06-24 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
CA3248209A1 (en) 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024104386A1 (zh) * 2022-11-16 2024-05-23 南京明德新药研发有限公司 一类含七元杂环的三齿缀合基团
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
CN122121898A (zh) * 2023-08-29 2026-05-29 甘纳合并子公司 聚糖缀合物组合物和方法
CN117466959B (zh) * 2023-10-30 2026-07-07 烟台药物研究所 一种肝靶向化合物、缀合物及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US8575123B2 (en) 2008-04-11 2013-11-05 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
EP4253395A3 (en) * 2012-08-06 2023-11-29 Alnylam Pharmaceuticals, Inc. Processes for the preparation of carbohydrate conjugated rna agents
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
US9943604B2 (en) * 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
US10358643B2 (en) * 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
US10513710B2 (en) * 2014-04-18 2019-12-24 University Of Massachusetts Exosomal loading using hydrophobically modified oligonucleotides
EP3137115B1 (en) 2014-05-01 2020-10-14 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
CR20160554A (es) * 2014-05-01 2017-03-07 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del factor b del complemento
WO2015168618A2 (en) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
US9834510B2 (en) * 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
JOP20170057B1 (ar) 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
AU2017296195A1 (en) * 2016-07-11 2019-01-24 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
WO2018067900A1 (en) 2016-10-06 2018-04-12 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
CN120247964A (zh) 2018-02-17 2025-07-04 箭头药业股份有限公司 三炔连接剂和使用方法
WO2021257916A1 (en) * 2020-06-18 2021-12-23 Arcturus Therapeutics, Inc. Una oligomers for the treatment of polyglutamine diseases
US20230227826A1 (en) * 2020-06-18 2023-07-20 Arcturus Therapeutics, Inc. Una oligomers for the treatment of polyglutamine diseases

Similar Documents

Publication Publication Date Title
AU2010227549B2 (en) Pharmaceutical composition containing a drug and siRNA
EP2773326B1 (en) Method for sterilely producing lipid-nucleic acid particles
ES2949172T3 (es) Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas
AU733310C (en) High efficiency encapsulation of charged therapeutic agents in lipid vesicles
JP2024533865A5 (cg-RX-API-DMAC7.html)
KR20230172570A (ko) 양이온성 지질 및 이의 조성물
JP2017518278A5 (cg-RX-API-DMAC7.html)
WO2012024233A2 (en) Zwitterionic lipids
JP2023515218A (ja) Pd-l1を標的とするための方法及び組成物
WO2024019770A1 (en) Methods of making ionizable lipids and lipid nanoparticles for mrna delivery
US20240175020A1 (en) Compositions of modified trems and uses thereof
US20030215489A1 (en) Chemosensitizing with liposomes containing oligonucleotides
KR20080106437A (ko) 갈락토스 유도체, 약물 담체 및 의약 조성물
CN116615233A (zh) 用于使生物分子在受试者中表达的系统和方法
WO2019063843A1 (en) COMPOSITIONS AND METHODS FOR RELEASE OF MRNA IN HEPATIC CELLS
US20250179492A1 (en) Compositions of modified trems and uses thereof
WO2025051994A1 (en) Ionizable lipid nanoparticles
CN120615126A (zh) 经修饰的免疫调节剂
JP7848179B2 (ja) リン脂質
WO1998009633A2 (en) Pharmaceutical compositions
KR20250158420A (ko) 신규 이온화지질 및 이를 포함하는 지질나노입자
TW202523695A (zh) 用於治療非酒精性脂肪性肝病之方法及組成物
KR20250092049A (ko) mRNA/LNP 백신의 면역원성 향상용 지질
WO2024035952A1 (en) Methods and compositions for modulating splicing at alternative splice sites
WO2025245188A2 (en) Methods of treating liver steatosis and non-alcoholic fatty liver disease